Navigation Links
IDM Pharma Announces Compliance With NASDAQ Minimum Bid Price Requirements
Date:2/20/2008

IRVINE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that it received notification from The NASDAQ Stock Market that the Company has regained compliance with NASDAQ Marketplace Rule 4450(a)(5), which requires listed companies to maintain a closing bid price of at least $1.00 per share.

On February 19, 2008, the closing price of the Company's common stock was $3.14 per share.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including statements regarding the Company's ability to comply with the minimum bid price requirements under the NASDAQ Marketplace Rules. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, whether the Company will be able to maintain a closing bid price of $1.00 per share or higher and risks relating to the Company's ability to comply with other NASDAQ requirements. Other risks affecting the Company and its drug development programs are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended September 30, 2007 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
2. Japan Backs Away from Making Real Changes to Its Rx Pharma Pricing Mechanism
3. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
4. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
5. Halleland Health Consulting Assists PBMs in Achieving URAC Accreditation for Pharmacy Benefit Management
6. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
7. EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
8. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
9. Nyer Medical Group Completes Acquisition of Minority Interest in Pharmacy Chain Subsidiary; Former Minority Shareholders Invest in Nyer Medical Group and Sign 3-Year Employment Agreements
10. KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE
11. His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work ... as “patient engagement.” The patient is doing more than filling out a survey; in ... “There is an increasing emphasis in health care and research on the importance of ...
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
Breaking Medicine Technology: